Skip to content
People

Eran Ovadya

Chief Financial Officer at NurExone Biologic.

Earliest Form D on file: Apr 2025

NurExone Biologic

Biotech

Chief Financial Officer · signer

  • Signed
  • Named
  • Size is amount sold

Filings

3
  • Jul 2, 2026

    Equity, option to acquire, security to be acquired, signed · Form D

    $442K

    of $442K

  • Aug 27, 2025

    Equity, option to acquire, security to be acquired, other, signed · Form D

    $148K

    of $243K

  • Apr 22, 2025

    Equity, option to acquire, security to be acquired, other, signed · Form D

    $1.6M

    of $3.8M

Network

At NurExone Biologic

6 people